MWNA
RUBY

Marshall Wace North America’s Rubius Therapeutics, Inc RUBY Stock Holding History

Marshall Wace North America’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-13,204
Closed -$239K – 1751
2019
Q1 		$239K Buy
+13,204
New +$203K ﹤0.01% 945
2018
Q4 		– Sell
-58,543
Closed -$1.41M – 1697
2018
Q3 		$1.41M Buy
+58,543
New +$1.34M 0.01% 552

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Marshall Wace North America's RUBY Position: Q2 2019 in Review

Marshall Wace North America sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2019, closing a stake of 13,204 shares — an estimated $239K sold.

Marshall Wace North America first reported a position in RUBY in Q3 2018 and held it in 2 quarters. The position peaked at $1.41M in Q3 2018. 69 funds tracked by Wall St. Rank hold RUBY as of Q2 2019.

  • Marshall Wace North America reported no remaining Rubius Therapeutics, Inc position as of Q2 2019 after selling out during the quarter.
  • Marshall Wace North America sold 13,204 Rubius Therapeutics, Inc shares in Q2 2019, an estimated $239K.
  • Marshall Wace North America first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 2 quarters.
  • Marshall Wace North America's Rubius Therapeutics, Inc position peaked at $1.41M in Q3 2018.
  • 69 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2019.

Based on Marshall Wace North America's 13F filing for Q2 2019, filed 14 Aug 2019.